skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 1,000  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: language: Russian remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
Material Type:
Article 		Add to My Research

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

Annals of the rheumatic diseases, 2010-10, Vol.69 (10), p.1809-1815 [Peer Reviewed Journal]

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;2015 INIST-CNRS ;Copyright: 2010 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;ISSN: 1468-2060 ;EISSN: 1468-2060 ;DOI: 10.1136/ard.2009.114264 ;PMID: 20551155 ;CODEN: ARDIAO

Full text available

Citations Cited by
2
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Material Type:
Article 		Add to My Research

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Annals of oncology, 2010-09, Vol.21 (9), p.1804-1809 [Peer Reviewed Journal]

2010 European Society for Medical Oncology ;2015 INIST-CNRS ;The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 2010 ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdq020 ;PMID: 20150572

Full text available

Citations Cited by
3
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
Material Type:
Article 		Add to My Research

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study

Circulation (New York, N.Y.), 2013-07, Vol.128 (3), p.237-243 [Peer Reviewed Journal]

2013 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2014 INIST-CNRS ;ISSN: 0009-7322 ;ISSN: 1524-4539 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.112.001139 ;PMID: 23770747 ;CODEN: CIRCAZ

Full text available

Citations Cited by
4
THE RISK FACTORS OF LETHAL COMPLICATIONS IN EARLY POSTOPERATIVE PERIOD IN PATIENTS, SUFFERING GASTROESOPHAGEAL ZONE MALIGNANCIES
THE RISK FACTORS OF LETHAL COMPLICATIONS IN EARLY POSTOPERATIVE PERIOD IN PATIENTS, SUFFERING GASTROESOPHAGEAL ZONE MALIGNANCIES
Material Type:
Article 		Add to My Research

THE RISK FACTORS OF LETHAL COMPLICATIONS IN EARLY POSTOPERATIVE PERIOD IN PATIENTS, SUFFERING GASTROESOPHAGEAL ZONE MALIGNANCIES

Klinična hìrurgìâ (Kiïv), 2016-02 (2), p.5-7 [Peer Reviewed Journal]

ISSN: 0023-2130 ;PMID: 27244907

Full text available

Citations Cited by
5
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
Material Type:
Article 		Add to My Research

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4105-4114 [Peer Reviewed Journal]

2015 INIST-CNRS ;2013 by American Society of Clinical Oncology 2013 ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.47.4189 ;PMID: 24101053

Full text available

Citations Cited by
6
Analysis of the Impact of Early Surgery on In-Hospital Mortality of Native Valve Endocarditis: Use of Propensity Score and Instrumental Variable Methods to Adjust for Treatment-Selection Bias
Analysis of the Impact of Early Surgery on In-Hospital Mortality of Native Valve Endocarditis: Use of Propensity Score and Instrumental Variable Methods to Adjust for Treatment-Selection Bias
Material Type:
Article 		Add to My Research

Analysis of the Impact of Early Surgery on In-Hospital Mortality of Native Valve Endocarditis: Use of Propensity Score and Instrumental Variable Methods to Adjust for Treatment-Selection Bias

Circulation (New York, N.Y.), 2010-03, Vol.121 (8), p.1005-1013 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0009-7322 ;ISSN: 1524-4539 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.109.864488 ;PMID: 20159831 ;CODEN: CIRCAZ

Full text available

Citations Cited by
7
Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies
Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies
Material Type:
Article 		Add to My Research

Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies

International journal of epidemiology, 2009-02, Vol.38 (1), p.143-153 [Peer Reviewed Journal]

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2008; all rights reserved. 2008 ;2009 INIST-CNRS ;ISSN: 0300-5771 ;EISSN: 1464-3685 ;DOI: 10.1093/ije/dyn160 ;PMID: 18775875 ;CODEN: IJEPBF

Full text available

Citations Cited by
8
Systematic Review and Meta-analysis of Circulatory Disease from Exposure to Low-Level Ionizing Radiation and Estimates of Potential Population Mortality Risks
Systematic Review and Meta-analysis of Circulatory Disease from Exposure to Low-Level Ionizing Radiation and Estimates of Potential Population Mortality Risks
Material Type:
Article 		Add to My Research

Systematic Review and Meta-analysis of Circulatory Disease from Exposure to Low-Level Ionizing Radiation and Estimates of Potential Population Mortality Risks

Environmental health perspectives, 2012-11, Vol.120 (11), p.1503-1511 [Peer Reviewed Journal]

2015 INIST-CNRS ;COPYRIGHT 2012 National Institute of Environmental Health Sciences ;COPYRIGHT 2012 National Institute of Environmental Health Sciences ;Copyright National Institute of Environmental Health Sciences Nov 2012 ;Distributed under a Creative Commons Attribution 4.0 International License ;2012 ;ISSN: 0091-6765 ;ISSN: 1552-9924 ;EISSN: 1552-9924 ;DOI: 10.1289/ehp.1204982 ;PMID: 22728254 ;CODEN: EVHPAZ

Full text available

Citations Cited by
9
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
Material Type:
Article 		Add to My Research

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

Journal of clinical oncology, 2012-03, Vol.30 (9), p.921-929 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0732-183X ;ISSN: 1527-7755 ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2011.35.7376 ;PMID: 22331954

Full text available

Citations Cited by
10
The excess mortality connected with COVID-19 pandemic
The excess mortality connected with COVID-19 pandemic
Material Type:
Article 		Add to My Research

The excess mortality connected with COVID-19 pandemic

Innovacionnaâ medicina Kubani (Online), 2022-06 (2), p.5-13 [Peer Reviewed Journal]

ISSN: 2541-9897 ;EISSN: 2541-9897 ;DOI: 10.35401/2541-9897-2022-25-2-5-13

Full text available

Citations Cited by
11
The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis
The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis
Material Type:
Article 		Add to My Research

The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis

European heart journal, 2003-03, Vol.24 (5), p.442-463 [Peer Reviewed Journal]

2004 INIST-CNRS ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1016/S0195-668X(02)00823-0 ;PMID: 12633546

Full text available

Citations Cited by
12
Rehabilitation of COVID-19 convalescents and its impact on cardiovascular endpoints: propensity score matching analysis
Rehabilitation of COVID-19 convalescents and its impact on cardiovascular endpoints: propensity score matching analysis
Material Type:
Article 		Add to My Research

Rehabilitation of COVID-19 convalescents and its impact on cardiovascular endpoints: propensity score matching analysis

Rossiĭskiĭ kardiologicheskiĭ zhurnal, 2023-12, Vol.28 (4S), p.5630 [Peer Reviewed Journal]

ISSN: 1560-4071 ;EISSN: 2618-7620 ;DOI: 10.15829/1560-4071-2023-5630

Full text available

Citations Cited by
13
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Material Type:
Article 		Add to My Research

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3517-3524 [Peer Reviewed Journal]

2014 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2012.48.4410 ;PMID: 23980084

Full text available

Citations Cited by
14
Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
Material Type:
Article 		Add to My Research

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

Circulation (New York, N.Y.), 2010-08, Vol.122 (6), p.597-602 [Peer Reviewed Journal]

2015 INIST-CNRS ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.110.940619 ;PMID: 20660803 ;CODEN: CIRCAZ

Full text available

Citations Cited by
15
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer
Material Type:
Article 		Add to My Research

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Clinical cancer research, 2014-08, Vol.20 (16), p.4240-4250 [Peer Reviewed Journal]

2015 INIST-CNRS ;2014 American Association for Cancer Research. ;2014 American Association for Cancer Research. 2014 ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-13-2752 ;PMID: 24919569 ;CODEN: CCREF4

Full text available

Citations Cited by
16
Adherence to a Healthy Diet According to the World Health Organization Guidelines and All-Cause Mortality in Elderly Adults From Europe and the United States
Adherence to a Healthy Diet According to the World Health Organization Guidelines and All-Cause Mortality in Elderly Adults From Europe and the United States
Material Type:
Article 		Add to My Research

Adherence to a Healthy Diet According to the World Health Organization Guidelines and All-Cause Mortality in Elderly Adults From Europe and the United States

American journal of epidemiology, 2014-11, Vol.180 (10), p.978-988 [Peer Reviewed Journal]

2015 INIST-CNRS ;The Author 2014. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. ;Copyright Oxford Publishing Limited(England) Nov 15, 2014 ;The Author 2014. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2014 ;Wageningen University & Research ;ISSN: 0002-9262 ;ISSN: 1476-6256 ;EISSN: 1476-6256 ;DOI: 10.1093/aje/kwu229 ;PMID: 25318818 ;CODEN: AJEPAS

Full text available

Citations Cited by
17
Cluster Analysis Results for Assessment of COVID-19-Related Mortality Differences Between Russian Regions
Cluster Analysis Results for Assessment of COVID-19-Related Mortality Differences Between Russian Regions
Material Type:
Article 		Add to My Research

Cluster Analysis Results for Assessment of COVID-19-Related Mortality Differences Between Russian Regions

Innovacionnaâ medicina Kubani (Online), 2023-03 (1), p.65-71 [Peer Reviewed Journal]

ISSN: 2541-9897 ;EISSN: 2541-9897 ;DOI: 10.35401/2541-9897-2023-26-1-65-71

Full text available

Citations Cited by
18
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)
Material Type:
Article 		Add to My Research

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN)

European heart journal, 2002-09, Vol.23 (18), p.1422-1432 [Peer Reviewed Journal]

2002 INIST-CNRS ;Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1053/euhj.2001.3158 ;PMID: 12208222

Full text available

Citations Cited by
19
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Material Type:
Article 		Add to My Research

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1227-1234 [Peer Reviewed Journal]

2009 INIST-CNRS ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2007.14.5466 ;PMID: 19188680

Full text available

Citations Cited by
20
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
Material Type:
Article 		Add to My Research

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

Annals of oncology, 2012-07, Vol.23 (7), p.1803-1808 [Peer Reviewed Journal]

2011 European Society for Medical Oncology ;2015 INIST-CNRS ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdr555 ;PMID: 22112969

Full text available

Citations Cited by

Results 1 - 20 of 1,000  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (965)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1996  (11)
  2. 1996 To 2002  (28)
  3. 2003 To 2009  (127)
  4. 2010 To 2017  (492)
  5. After 2017  (344)
  6. More options open sub menu

Resource Type 

  1. Articles  (998)
  2. Reviews  (1)
  3. Books  (1)
  4. More options open sub menu

Language 

  1. English  (616)
  2. Japanese  (31)
  3. Ukrainian  (24)
  4. German  (5)
  5. French  (1)
  6. Portuguese  (1)
  7. Spanish  (1)
  8. Lithuanian  (1)
  9. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait